Changes to the Code
H.R. 1143 · Medicare IVIG Access Enhancement Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1395u Provisions relating to the administration of part B
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1842(o)(8) of the Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting
and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)
afterof 2012
.
§ 1395u(o)–(p)
Start of § 1395u to (o)(6) unchanged ·
(7) There shall be no administrative or judicial review under section 1395ff of this title, section 1395oo of this title, or otherwise, of determinations of payment amounts, methods, or adjustments under paragraphs (4) through (6).
(8) In the case of intravenous immune globulin described in section 1395x(s)(2)(Z) of this title that are furnished on or after January 1, 2024, to an individual by a supplier in the patient’s home, the Secretary shall provide for a separate bundled payment to the supplier for all items and services related to the administration of such intravenous immune globulin to such individual in the patient’s home during a calendar day in an amount that the Secretary determines to be appropriate, which may be based on the payment established pursuant to subsection (d) of section 101 of the Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012[inserted: and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)]. For purposes of the preceding sentence, such separate bundled payment shall not apply in the case of an individual receiving home health services under section 1395fff of this title.
(p) Requiring submission of diagnostic information
(1) Each request for payment, or bill submitted, for an item or service furnished by a physician or practitioner specified in subsection (b)(18)(C) for which payment may be made under this part shall include the appropriate diagnosis code (or codes) as established by the Secretary for such item or service.
Rest of § 1395u unchanged ·
42 U.S.C. § 1395x Definitions
2 changes the bill asks for here, 2 carried out
- Carried out:
in subsection (s)(2)(Z), by inserting
(and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)
afterprimary immune deficiency diseases
; and - Carried out:
in subsection (zz), by inserting
(or, beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)
afterprimary immune deficiency disease
.
§ 1395x(s)(2)(Y)–(AA)
Start of § 1395x to (s)(2)(X) unchanged ·
(Y) diabetes screening tests (as defined in subsection (yy));
(Z) intravenous immune globulin, and items and services furnished on or after January 1, 2024, related to the administration of intravenous immune globulin, for the treatment of primary immune deficiency diseases [inserted: (and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy) ]in the home (as defined in subsection (zz));
(AA) ultrasound screening for abdominal aortic aneurysm (as defined in subsection (bbb)) for an individual—
(i) who receives a referral for such an ultrasound screening as a result of an initial preventive physical examination (as defined in subsection (ww)(1));
§ 1395x(yy)–(aaa)
(s)(2)(AA)(ii)–(yy)(2)(F)(iv) unchanged ·
(3) The Secretary shall establish standards, in consultation with appropriate organizations, regarding the frequency of diabetes screening tests, except that such frequency may not be more often than twice within the 12-month period following the date of the most recent diabetes screening test of that individual.
(zz) Intravenous immune globulin The term “intravenous immune globulin” means an approved pooled plasma derivative for the treatment in the patient’s home of a patient with a diagnosed primary immune deficiency disease[inserted: (or], [inserted: beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy), ]but not including items or services furnished before January 1, 2024, related to the administration of the derivative, if a physician determines administration of the derivative in the patient’s home is medically appropriate.
(aaa) Extended care in religious nonmedical health care institutions
(1) The term “home health agency” also includes a religious nonmedical health care institution (as defined in subsection (ss)(1)), but only with respect to items and services ordinarily furnished by such an institution to individuals in their homes, and that are comparable to items and services furnished to individuals by a home health agency that is not religious nonmedical health care institution.
Rest of § 1395x unchanged ·